Sarepta Therapeutics named Michael Severino, formerly CEO of Tessera Therapeutics, as its chief executive starting Tuesday. Severino replaces Doug Ingram, who announced plans to retire after nearly a decade leading the Duchenne-focused biotech. Sarepta’s leadership transition lands as the company continues to navigate ongoing scrutiny around its gene therapy safety and effectiveness and works through recent share-price pressure. Investors will look for whether Severino’s operating priorities recalibrate development strategy and regulatory engagement as Sarepta attempts to restore confidence in its Duchenne franchise.